Author

A. E. Eakin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:virus· 2 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

C. D. Weiss· 3 shared K. J. Erlandson· 3 shared R. Vassell· 3 shared S. Lusvarghi· 3 shared S. N. Neerukonda· 3 shared W. Wang· 3 shared L. Bentley· 2 shared L. C. Katzelnick· 2 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

C. D. Weiss

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

S. Lusvarghi, S. D. Pollett, S. N. Neerukonda, W. Wang, R. Wang, R. Vassell, N. J. Epsi, A. C. Fries, B. K. Agan, D. A. Lindholm, C. J. Colombo, R. Mody, E. C. Ewers, T. Lalani, A. Ganesan, , C. D. Weiss

A third dose of Pfizer/BioNTech vaccine significantly boosts Omicron neutralizing antibodies, while convalescent sera and therapeutic antibodies show variable and often low neutralization.

bioRxiv · Dec 22, 2021Microbiology

SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity

S. N. Neerukonda, R. Vassell, S. Lusvarghi, R. Wang, F. Echegaray, L. Bentley, A. E. Eakin, K. J. Erlandson, L. C. Katzelnick, C. D. Weiss, W. Wang

This study evaluates the neutralization resistance and spike protein properties of SARS-CoV-2 B.1.617 variants, finding modest resistance to sera and therapeutic antibodies, but enhanced cleavage and fusogenic activity in Delta variants.

bioRxiv · Nov 5, 2021Microbiology

Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects

S. Lusvarghi, W. Wang, R. Herrup, S. N. Neerukonda, R. Vassell, L. Bentley, A. E. Eakin, K. J. Erlandson, C. D. Weiss

The paper evaluates resistance of 25 therapeutic antibodies to SARS-CoV-2 variants with multiple spike substitutions, finding key substitutions predict resistance but other substitutions can modify it unpredictably.

bioRxiv · Jul 16, 2021Microbiology